Louie, A. V., Senan, S., Patel, P., Ferket, B. S., Lagerwaard, F. J., Rodrigues, G., … Hunink, M. (2014). When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I lung cancer? A decision analysis. In Journal of Clinical Oncology (Vol. 32, pp. 7534–7534). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.7534

Louie, Alexander V., Suresh Senan, Pretesh Patel, Bart S. Ferket, Frank J. Lagerwaard, George Rodrigues, Joseph Kamel Salama, Christopher Ryan Kelsey, David Palma, and Myriam Hunink. “When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I lung cancer? A decision analysis.” In Journal of Clinical Oncology, 32:7534–7534. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.7534.

Louie AV, Senan S, Patel P, Ferket BS, Lagerwaard FJ, Rodrigues G, et al. When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I lung cancer? A decision analysis. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 7534–7534.

Louie, Alexander V., et al. “When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I lung cancer? A decision analysis.” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 7534–7534. Crossref, doi:10.1200/jco.2014.32.15_suppl.7534.

Louie AV, Senan S, Patel P, Ferket BS, Lagerwaard FJ, Rodrigues G, Salama JK, Kelsey CR, Palma D, Hunink M. When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I lung cancer? A decision analysis. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 7534–7534.